Citi analyst Patrick Donnelly downgraded Hologic to Neutral from Buy with a price target of $85, down from $95. The firm believes current fiscal 2025 estimates are too high and will likely need to be lowered, driven by normalization of demand. Citi believes Hologic’s 2025 outlook will be below consensus and says that while the stock’s valuation remains reasonable, additional multiple expansion is a “more challenging debate.”
